Glucose transporter inhibitor-conjugated insulin mitigates hypoglycemia by Wang, J. et al.
Glucose transporter inhibitor-conjugated insulin
mitigates hypoglycemia
Jinqiang Wanga,b, Jicheng Yuc, Yuqi Zhangc, Anna R. Kahkoskad, Zejun Wanga,b, Jun Fanga, Julian P. Whiteleggee,
Song Lia,f, John B. Bused, and Zhen Gua,b,g,h,1
aDepartment of Bioengineering, University of California, Los Angeles, CA 90095; bCalifornia NanoSystems Institute, University of California, Los Angeles, CA
90095; cJoint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Raleigh, NC 27514;
dDepartment of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC 27599; eThe Pasarow Mass Spectrometry Laboratory, The Jane
and Terry Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine, University of California, Los Angeles, CA 90095;
fDepartment of Medicine, University of California, Los Angeles, CA 90095; gJonsson Comprehensive Cancer Center, University of California, Los Angeles,
CA 90024; and hCenter for Minimally Invasive Therapeutics, University of California, Los Angeles, CA 90095
Edited by Hongjie Dai, Department of Chemistry, Stanford University, Stanford, CA, and approved April 17, 2019 (received for review February 4, 2019)
Insulin therapy in the setting of type 1 and advanced type 2 diabetes is
complicated by increased risk of hypoglycemia. This potentially fatal
complication could bemitigated by a glucose-responsive insulin analog.
We report an insulin-facilitated glucose transporter (Glut) inhibitor
conjugate, in which the insulin molecule is rendered glucose-responsive
via conjugation to an inhibitor of Glut. The binding affinity of this
insulin analog to endogenous Glut is modulated by plasma and tissue
glucose levels. In hyperglycemic conditions (e.g., uncontrolled diabetes
or the postprandial state), the in situ-generated insulin analog−Glut
complex is driven to dissociate, freeing the insulin analog and
glucose-accessible Glut to restore normoglycemia. Upon overdose, en-
hanced binding of insulin analog to Glut suppresses the glucose trans-
port activity of Glut to attenuate further uptake of glucose. We
demonstrate the ability of this insulin conjugate to regulate blood glu-
cose levels within a normal range while mitigating the risk of hypogly-
cemia in a type 1 diabetic mouse model.
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Diabetes mellitus affects more than 400 million people acrossthe world (1–3). The treatment for type 1 and advanced type
2 diabetes is multiple daily injections or continuous infusion of
exogenous insulin (1, 2, 4). However, the benefits of insulin
therapy are often not fully realized, due to the risk of hypogly-
cemia associated with insulin overdose, which can result in seizure,
coma, and death (5). Therefore, tremendous efforts have been
devoted to the development of smart insulin delivery systems that
mimic the glucose-dependent dynamic insulin secretion of β-cells,
thereby reducing hyperglycemic condition and mitigating the risk
of insulin-induced hypoglycemia associated with a miscalculated
exogenous insulin dose (6, 7). To this end, chemically driven
synthetic closed-loop insulin delivery systems integrating phenyl-
boronic acid (7–16), glucose-binding protein (17–20), and glucose
oxidase (21–26) have been extensively studied. However, synthetic
strategies to tightly regulate blood glucose levels with a low risk of
hypoglycemia remain elusive in clinical practice (27).
Here, we propose to expand the safety margin of insulin by
simply conjugating insulin with a reversible glucose transporter
(Glut) inhibitor. Glut is a family of transmembrane proteins that
facilitate the transport of glucose across plasma membranes (28).
Various compounds are able to competitively inhibit the glucose
transport activity of Glut (29–31). Due to the presence of the
Glut inhibitor, the insulin analog can reversibly and dynamically
bind to Glut on cell membranes with an affinity modulated by
surrounding glucose concentration, rendering the insulin mole-
cule glucose-responsive (Fig. 1). Upon s.c. injection, this insulin
analog can bind to insulin receptors (IR) as well as endogenous
Glut, establishing an in situ-generated reservoir of insulin ana-
log−Glut complex (Fig. 1). Upon a glucose challenge, such as the
glucose rise associated with a meal, the insulin analog−Glut
complexes dissociate to liberate free Glut on plasma membranes
as well as free insulin analog into interstitial fluids and plasma.
The free insulin analog can subsequently bind to IR to trigger the
translocation of Glut4 to cell membranes and enhance glucose
clearance into muscle and fat. Meanwhile, the Glut, which is
previously inaccessible to glucose as part of the insulin analog−
Glut complex, can enhance the blood glucose clearance. In ex-
cess doses, the insulin analog induces overexpression of Glut on
plasma membranes and subsequently triggers the glucose uptake
by cells, which could potentially induce hypoglycemia; however,
the formation of the glucose-responsive insulin analog−Glut
complexes can suppress the glucose transport efficiency of Glut,
therefore reducing the hypoglycemic risk.
Results
Glut-i2, a reversible Glut inhibitor with a low dissociation constant
and high affinity for Glut4 and Glut1 (32), was selected for our
study. Glut-i2 was integrated with a single terminal amino group to
give Glut-i2−NH2 (SI Appendix, Scheme S1 and Figs. S1–S5) (32).
Next, Glut-i2−NH2 was conjugated to insulin via a bifunctional linker
(17) succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate to
give insulin−Glut-i2 conjugate (designated i-insulin), which was con-
firmed by measuring the molecular weight via the matrix-assisted
laser desorption/ionization with a time-of-flight analyzer (SI Ap-
pendix, Fig. S6), while the modification was validated on A1 of in-
sulin (SI Appendix, Fig. S7).
To test the binding ability of the i-insulin toward Glut, it was
labeled with sulfo-Cyanine 5 (Cy5-i-insulin) and used to treat
erythrocyte ghost, a widely used Glut carrier (SI Appendix, Fig.
S8) (33, 34). After 30-min incubation with i-insulin at room
temperature, the erythrocyte ghosts showed a high fluorescence
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intensity localized on the membranes, whereas the surrounding
solvent showed a slightly weaker fluorescence (Fig. 2A). Control
erythrocyte ghosts treated with Cy5-labeled native insulin only
showed weak fluorescence comparable to the background (Fig.
2B). Moreover, the amount of Cy5-i-insulin bound to erythrocyte
ghosts increased along with the increase of the concentration of
free Cy5-i-insulin (SI Appendix, Fig. S9), and the Kd was mea-
sured as 13 nM (SI Appendix, Figs. S10 and S11 and Eqs. S1 and
S2). The binding rate of i-insulin toward erythrocyte ghost was
evaluated. Within 2 min of the addition of Cy5-i-insulin to the
erythrocyte ghost solution, high fluorescence intensity localized
on the erythrocyte membranes was observed (SI Appendix, Fig.
S12A). A concurrent rapid decrease in the fluorescence intensity
of the supernatant was also observed (SI Appendix, Fig. S13).
Next, the in vitro release kinetics of i-insulin was investigated by
diluting the Cy5-i-insulin−treated erythrocyte ghost solution and
observing the fluorescent signal. A sharp decrease in fluorescence
intensity was noted for all Cy5-i-insulin−treated erythrocyte ghosts
within 2 min after a twofold, fourfold, and 10-fold dilution (SI
Appendix, Fig. S12B).
Cy5-i-insulin−treated erythrocyte ghosts were further treated
with glucose solutions at varying glucose concentrations of 0,
400, 800, and 1,600 mg/dL. The fluorescence intensity gradually
decreased with increased glucose concentrations, consistent
with the proposed dissociation of i-insulin−Glut complexes
(Fig. 2 C and D). The glucose-responsive dissociation of i-
insulin−Glut complex was further tested at physiological-
relevant concentrations (1 and 5 nM) of i-insulin (35). The
concentration of i-insulin increased in the supernatant as the
glucose concentration was increased (Fig. 2 E and F). A 100%
increase in the concentration of supernatant insulin was ob-
served as the glucose concentration increased from 0 mg/dL to
400 mg/dL for both the 1- and 5-nM concentrations.
Next, the ability of i-insulin to regulate blood glucose levels
was evaluated in the type 1 diabetic mice induced by streptozo-
tocin (STZ). With s.c. injection, the i-insulin−treated mice sus-
tained normoglycemia below 200 mg/dL for more than 10 h (Fig.
3A), whereas mice treated with native insulin showed less than
4 h of normoglycemia (Fig. 3A). Prolonged s.c. retention of i-insulin
at the injection site compared with native insulin was observed (SI
Fig. 1. Schematic of regulating the glucose-transport activity with insulin analog (IA; in this study, i-insulin serves as a model analog). Insulin analog can bind
to Glut in a glucose-responsive manner. Upon injection and in normoglycemia, insulin analog achieves a regular blood glucose clearance rate, and an insulin
analog−Glut complex reservoir is formed. Upon a glucose challenge, increased blood glucose levels result in the release of insulin analog from the insulin
analog−Glut complex, which subsequently binds to IR to trigger the translocation of Gluts to cell membranes. With dissociation of insulin analog, glucose-
inaccessible insulin analog-bound Glut becomes free Glut, enhancing excess blood glucose clearance. Upon an excess insulin analog injection (i.e., overdose),
the formation of the insulin analog−Glut complex attenuates the glucose transport activity of Glut, therefore mitigating hypoglycemia risk.

















Appendix, Fig. S14). Of note is that mice treated with i-insulin
showed negligible hypoglycemia (Fig. 3A). When a second injection
of i-insulin or native insulin was administered 3 h posttreatment when
normoglycemia was achieved, i-insulin− treated mice showed a
significantly extended normoglycemia period with negligible hy-
poglycemia, while native insulin-treated mice showed marked
Fig. 2. The in vitro study of i-insulin interaction with erythrocyte ghosts. Erythrocyte ghosts were treated with sulfo-Cy5−labeled (A) i-insulin or (B) insulin and
subsequently observed using confocal microscopy. The concentration of i-insulin or insulin was set as 1 μM. (Scale bar, 50 μm.) (Insets) The representative enlarged
images. (Scale bar, 5 μm.) The fluorescence intensity on plasma membranes was analyzed using software ImageJ. (C) The i-insulin displacement by glucose. The
glucose was set as 0, 400, 800, and 1,600 mg/dL. (Scale bar, 50 μm.) (D) The fluorescence intensity on plasmamembranes was analyzed using software ImageJ. Data
are presented as mean + SD (n = 10). (E and F) The glucose-triggered i-insulin release from erythrocyte ghosts. The glucose concentration was set as 0, 100, 200,
300, and 400 mg/dL, while the i-insulin was set as (E) 1 nM and (F) 5 nM. Human recombinant insulin ELISA kit was used to measure the i-insulin level in the
supernatant. The average i-insulin level in the supernatant at 0 mg/dL of glucose was set as 100%. The data are presented as mean + SD (n = 3).
Fig. 3. The in vivo characterization of i-insulin. (A) The blood glucose regulation effect of s.c.-injected i-insulin toward STZ-induced type 1 diabetic mouse. The
dose was set as 6 mg/kg. Native insulin (1.5 mg/kg) was used as a positive control. PBS was used as a negative control. Data are presented as mean ± SD (n = 5). The
black arrow indicates the injection of i-insulin or insulin. (B) The blood glucose level change of mice treated with two sequential injections. A second injection was
given at 3 h post first treatment. The doses were set to 6 and 1.5 mg/kg for i-insulin and insulin, respectively. Data are presented as mean ± SD (n = 5). The black
arrows indicate the time of injection. (C) Hypoglycemia induction on healthy C57BL/6J mice. The doses of i-insulin and insulin were set as 3 and 0.75 mg/kg,
respectively. The i-insulin and insulin were s.c. injected. Data are presented as mean ± SD (n = 5). The black arrow indicates the starting time of treatment. (D and
E) IPGTT. The therapeutic dose was set as 6 and 1.5 mg/kg for i-insulin and insulin, respectively. Glucose was given at 3 h posttreatment at a dose of 1.5 g/kg.
Healthy mice were used as the control. Data are presented as mean ± SD (n = 5). The black arrow indicates the glucose injection. The blood glucose response to
IPGTT in terms of blood glucose AUC was analyzed using OriginPro 2017. The P values were calculated using one-way ANOVA with a Tukey post hoc test.
Statistical significance P value was calculated to be smaller than 0.0001. ***P < 0.001. (F) IPGTT-triggered i-insulin release. Glucose (1.5 g/kg) was given at 3 h
posttreatment. Blood plasma was collected and measured using a human insulin ELISA. The blood insulin level just before injection was set as 100%. Data were
presented as mean ± SD (n = 4).
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hypoglycemia (Fig. 3B). This hypoglycemia-mitigating effect of
i-insulin was further evaluated on healthy mice. Following s.c.
injection, native insulin induced severe hypoglycemia represented
by blood glucose levels of ∼60 mg/dL. In contrast, i-insulin−treated
mice did not show glucose levels below 100 mg/dL (Fig. 3C).
An i.p. glucose tolerance test (IPGTT) was also performed at
3 h posttreatment. A spike in blood glucose levels was observed
for all groups; however, only i-insulin−treated mice and healthy
mice showed blood glucose levels back to normal range within 2
h (Fig. 3D). The enhanced ability of i-insulin in regulating blood
glucose levels compared with native insulin was confirmed by the
area under curve (AUC) analyses (Fig. 3E). Moreover, a peak of
plasma insulin associated with IPGTT was observed without
delay in the i-insulin−treated mice (Fig. 3F).
The toxicity of i-insulin to the liver and kidney was further eval-
uated via serum albumin (ALB), alkaline phosphatase (ALP), ala-
nine aminotransferase (ALT), aspartate transaminase (AST), blood
urea nitrogen (BUN), and creatinine (CREAT) levels, on days 1
and 3 after the s.c. injection of i-insulin (Fig. 4A). No significant
differences across any biochemical measures were observed. In
addition, there were no obvious changes in blood cell counts (Fig.
4B). Meanwhile, negligible neutrophil infiltration was observed at
treated skin sites, as shown in the hematoxylin and eosin (H&E)
stain results (Fig. 4C). Moreover, the total levels of IgM and IgG
associated with both healthy mice and diabetic mice were in-
significantly changed during the 2-wk treatment (SI Appendix, Fig.
S15) (36, 37). Systemic evaluation of the specific immune responses
against i-insulin upon variation of treatment doses, frequencies, and
routes are required for further translation (37, 38).
Discussion
Bioresponsive insulin-mediated treatment has the potential to
revolutionize the current diabetes treatment. An insulin molecule
with the properties of glucose responsiveness and hypoglycemia
mitigation would offer a novel approach to regulate blood glucose
levels with low risk for hypoglycemia. In this study, we engineered
such a molecule via conjugation of insulin to the Glut competitive
inhibitor Glut-i2 to allow i-insulin for reversible and glucose-
responsive binding to endogenous Glut. In vitro, the i-insulin
was able to rapidly bind to Glut on erythrocyte ghosts at low
blood glucose concentrations, while releasing free and glucose-
accessible Glut in response to hyperglycemia. Upon a glucose
challenge, i-insulin was liberated from the i-insulin−Glut complex
for subsequent binding to IR and rapid blood glucose clearance.
Upon s.c. injection in type 1 diabetic mice, i-insulin showed a
significantly more durable normoglycemia effect with negligible
hypoglycemia, even after a second injection. This result was
further confirmed with studies showing that i-insulin only slightly
lowered blood glucose of healthy mice, while native insulin in-
duced severe hypoglycemia. Upon a glucose challenge, a portion
of i-insulin was released from i-insulin−Glut complex directly to
the interstitial fluid and plasma. Remarkably, the direct release
Fig. 4. Toxicity and biocompatibility evaluation of i-insulin in diabetic mice. (A) Serum ALB, ALP, ALT, AST, BUN, and CREAT concentration on day 1 or 3
posttreatment of i-insulin. Data are presented as mean ± SD (n = 5). (B) Red blood cell (RBC), white blood cell (WBC), platelet (PLT), monocyte (MONO),
neutrophil (NEUT), basophil (BASO), and eosinophil (EO) were counted on day 1 or 3 posttreatment of i-insulin. D1, day 1 posttreatment; D3, day 3 post-
treatment; N, no-treatment group. Data are presented as mean + SD (n = 5). (C) H&E staining of the skin, where i-insulin was s.c. administered, from the
diabetic mice. (Scale bar, 300 μm.)

















of i-insulin to the interstitial environment may help i-insulin rapidly
reach IRs on target cells. In addition, the release of i-insulin from
the i-insulin−Glut complex generates glucose-accessible free Glut
to enhance the excess glucose clearance from blood.
This glucose transporter inhibitor-mediated insulin can be
further optimized, regarding response kinetics, effective dura-
tion, and Glut specificity, through varying the component(s) of
glucose transporter inhibitor, insulin, and spacer. Moreover, this
glucose-responsive insulin can be further integrated with painless
transdermal microneedle array patch to generate a new version
of “smart insulin patch” (SI Appendix, Fig. S16) (39, 40) or oral
delivery systems to form “smart insulin pills” (41).
Materials and Methods
Experimental procedures for insulin analog synthesis and in vitro glucose-
triggered insulin release, procedures for animal experiment, and additional
control experiments are provided in SI Appendix. The animal study protocol
was approved by the Institutional Animal Care and Use Committee at North
Carolina State University and the University of California, Los Angeles.
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